USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies

USC PE-GCS:优化西班牙裔结直肠癌患者参与癌症基因组特征研究

基本信息

  • 批准号:
    10294884
  • 负责人:
  • 金额:
    $ 371.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-22 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Colorectal Cancer (CRC) is the second leading cause of cancer death in the US. Hispanic/Latinos are the largest and fasting growing ethnic group in the US, and cancer is the leading cause of death among H/L in the US. Therefore, we need to fully understand the full complexity of the molecular etiology of cancer in this ethnic group. For instance, although incidence rates of CRC are lower among Latinos as compared to Whites or African Americans, Hispanics with metastatic disease have shorter overall survival when adjusted for health care setting, demographics, disease characteristics and treatment factors. H/L also tend to be diagnosed at a younger age and with higher stage, and we have previously reported that Mexican H/L in California have the greatest proportion of young (<50 years of age) diagnoses compared to other H/L subgroups. Moreover, Mexican H/L showed higher prevalence of rectal cancer cases compared to other H/L and NHW. Although socio-economics and access to care might influence these differences, we need to take a complete look at the biology of disease in this ethnic group to determine once and for all if these clinical differences are related to differences in molecular etiology. The Cancer Genome Atlas has provided a deep overview of the molecular taxonomy of CRC in 594 cases, however, less than 1% of the cases (n=5) were H/L. Therefore, it is imperative for us to take more detailed assessment of the molecular genomic landscape of CRC in H/L. One of the major issues likely limiting our ability to perform these large genomic initiatives in minority patients is that Patient or Participant Engagement practices may not been investigated to identify best practices for accruing and consenting patients into clinical translational biomedical research studies. This concept of Participant Engagement is critically important for both the patients and the translational cancer research community. Optimizing and improving our approaches for directly engaging patients at initial contact, throughout the course of a translational genomic study, and during the time of return of results is likely to lead to stronger relationships between the medical community and patients, but could also lead to significant improvement in outcomes for patients and for the cancer care community as a whole. As such, we propose the creation of the USC Center for Optimization of Participant Engagement in Cancer Characterization (COPECC) with a focus on optimizing the engagement of Latinos in CRC Genomic Characterization research studies. USC COPECC would serve as a member of the NCI U2C Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Our investigative team includes experts in all relevant areas of research for genomic characterization, participant engagement, and engagement optimization. We have an established platform for consenting patients into cancer genomics studies that will serve as a standard process. The overall goal of USC COPECC is to generate results on participant engagement optimization and CRC genomic research that will be shared with the broader community to distribute best practices for engaging Latinos in hopes of improving overall outcomes for CRC in this underserved population.
摘要 结直肠癌(CRC)是美国癌症死亡的第二大原因。西班牙裔/拉丁裔是最大的 在美国,癌症是H/L中死亡的主要原因。 因此,我们需要充分了解这一族群癌症分子病因的全部复杂性。 例如,尽管拉丁美洲人的CRC发病率低于白人或非洲人, 美国人,西班牙裔转移性疾病有较短的总生存期时,调整医疗保健设置, 人口统计学、疾病特征和治疗因素。H/L也倾向于在年轻时被诊断出来 和更高的阶段,我们以前曾报道,墨西哥H/L在加州有最大的 与其他H/L亚组相比,年轻(<50岁)诊断的比例。墨西哥H/L 显示直肠癌病例的患病率高于其他H/L和NHW。虽然社会经济 获得医疗服务可能会影响这些差异,我们需要全面了解疾病的生物学, 以一劳永逸地确定这些临床差异是否与分子水平的差异有关。 病因学癌症基因组图谱提供了一个深入的概述CRC的分子分类在594 例H/L病例中H/L不足1%。因此,我们必须采取更详细的措施, H/L中CRC的分子基因组景观评估。可能限制我们能力的主要问题之一 在少数民族患者中实施这些大型基因组计划的关键是患者或参与者参与实践 可能未进行调查,以确定获得患者同意进入临床转化的最佳实践 生物医学研究。这种参与者参与的概念对患者和患者都至关重要。 和转化型癌症研究团体。优化和改进我们的方法, 在最初接触患者时,在整个翻译基因组研究过程中, 结果的回报可能会导致医学界和患者之间更紧密的关系,但 也可能导致患者和癌症护理社区的结果显着改善, 整体因此,我们建议建立南加州大学参与者参与优化中心, 癌症表征(COPECC),重点是优化拉丁美洲人参与CRC基因组学 表征研究。USC COPECC将作为NCI U2 C参与者的成员 参与和癌症基因组测序(PE-CGS)网络。我们的调查团队包括专家, 基因组表征、参与者参与和参与的所有相关研究领域 优化.我们有一个既定的平台,允许患者同意进行癌症基因组学研究, 作为一个标准过程。南加州大学COPECC的总体目标是产生参与者参与的结果 优化和CRC基因组研究,将与更广泛的社区分享,以最好地分发 鼓励拉丁美洲人参与的做法,希望改善CRC在这一服务不足人口中的总体成果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN D. CARPTEN其他文献

JOHN D. CARPTEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN D. CARPTEN', 18)}}的其他基金

Admin-Core-001
管理核心-001
  • 批准号:
    10710089
  • 财政年份:
    2022
  • 资助金额:
    $ 371.25万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10492734
  • 财政年份:
    2021
  • 资助金额:
    $ 371.25万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10294885
  • 财政年份:
    2021
  • 资助金额:
    $ 371.25万
  • 项目类别:
USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies
USC PE-GCS:优化西班牙裔结直肠癌患者参与癌症基因组特征研究
  • 批准号:
    10492733
  • 财政年份:
    2021
  • 资助金额:
    $ 371.25万
  • 项目类别:
USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies
USC PE-GCS:优化西班牙裔结直肠癌患者参与癌症基因组特征研究
  • 批准号:
    10696237
  • 财政年份:
    2021
  • 资助金额:
    $ 371.25万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10696239
  • 财政年份:
    2021
  • 资助金额:
    $ 371.25万
  • 项目类别:
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
非裔美国女性乳腺癌的体细胞突变及其病因决定因素
  • 批准号:
    10335127
  • 财政年份:
    2019
  • 资助金额:
    $ 371.25万
  • 项目类别:
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
非裔美国女性乳腺癌的体细胞突变及其病因决定因素
  • 批准号:
    10558682
  • 财政年份:
    2019
  • 资助金额:
    $ 371.25万
  • 项目类别:
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
非裔美国女性乳腺癌的体细胞突变及其病因决定因素
  • 批准号:
    10091976
  • 财政年份:
    2019
  • 资助金额:
    $ 371.25万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10481849
  • 财政年份:
    2018
  • 资助金额:
    $ 371.25万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 371.25万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 371.25万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 371.25万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 371.25万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 371.25万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 371.25万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 371.25万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 371.25万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 371.25万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 371.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了